行情

CORT

CORT

Corcept医疗
NASDAQ

实时行情|Nasdaq Last Sale

11.65
-0.35
-2.92%
已收盘, 16:35 04/03 EDT
开盘
12.00
昨收
12.00
最高
12.49
最低
11.57
成交量
112.00万
成交额
--
52周最高
17.48
52周最低
9.55
市值
13.35亿
市盈率(TTM)
15.15
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CORT价格均价为17.20,最高价位26.00,最低价为11.00。

EPS

CORT 新闻

更多
  • Why You Shouldn't Bet Against Corcept Therapeutics (CORT) Stock
  • Zacks · 3天前
  • CORCEPT THERAPEUTICS PUBLISHES ABSTRACT IN THE JOURNAL OF THE ENDOCRINE SOCIETY
  • GlobeNewswire · 4天前
  • Update: Corcept Therapeutics (NASDAQ:CORT) Stock Gained 88% In The Last Five Years
  • Simply Wall St. · 03/26 17:06
  • Healthcare And Biotechnology Dashboard - Update
  • Seeking Alpha - Article · 03/24 18:33

所属板块

制药
-0.13%
制药与医学研究
-0.22%

热门股票

代码
价格
涨跌幅

CORT 简况

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.
展开

微牛提供Corcept Therapeutics Incorporated(NASDAQ-CORT)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CORT股票新闻,以帮助您做出投资决策。